Floatz logo

Ifosfamide

Small Cell Lung Cancer

Peking Union Medical College HospitalPhase 3Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
65/ 100

Competitive context

291 Active assets in the Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Benmelstobart
Yayi He
Phase 4A
Adebelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BBB
vx-970
National Cancer Institute (NCI)
Phase 2BBB
Veliparib
Central European Society for Anticancer Drug Research
Phase 2BB
Irinotecan
Sichuan University
Phase 4BB

View all 50 →

Same molecule, other indications

Ifosfamide is also rated in:

angioimmunoblastic T-cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary mediastinal large B-cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →